Clinical trials: Neuroendocrine Cancer
Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
This randomized phase II trial studies how well everolimus and octreotide acetate with or without bevacizumab works in treating patients with pancreatic neuroendocrine tumors that cannot be removed by surgery and have spread…
- Conditions
- Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma, Pancreatic Neuroendocrine Tumor G1
- Trial name
- NCT01229943
- Testing
- Bevacizumab, Everolimus, Octreotide Acetate
- Where
- 394 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Prostate Cancer
Survivorship Promotion In Reducing IGF-1 Trial
This is a prospective, single-center randomized trial with three arms, and an allocation ratio of 1:1:1. The study design is an efficacy study to evaluate the effect of metformin and coach-directed behavioral weight loss versus…
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer
- Trial name
- SPIRIT (NCT02431676)
- Testing
- Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma, Neoplasm Metastasis
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
This experiment will test the safety and effectiveness of a treatment for melanoma in which certain lymphocytes (a type of white blood cell) are taken from the patient, grown in the laboratory, and returned after the patient's…
- Trial name
- NCT00001832
- Testing
- gp100:209-217 (210M), Montanide ISA-51, IL-2
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Vestibular Neuronitis, Vestibular Neuronitis, Bilateral
Recovery of Visual Acuity in People With Vestibular Deficits
The purpose of this study is to determine whether exercises relieve the symptoms of dizziness and imbalance in people with vestibular deficits and improves the ability to see clearly during head movements.
- Conditions
- Vestibular Neuronitis, Vestibular Neuronitis, Bilateral, Vestibular Schwannoma
- Trial name
- NCT00411216
- Testing
- Control exercises, gaze stabilization exercises
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Emory University
Age-Related Macular Degeneration
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
This clinical study was designed to compare the safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those neovascular age-related macular degeneration (nAMD) patients with…
- Trial name
- MERLIN (NCT03710564)
- Testing
- Brolucizumab, Aflibercept
- Where
- 61 sites in United States, Puerto Rico
- Volunteers
- 535 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Melanoma
Fecal Microbiota Transplant (FMT) in Melanoma Patients
The main goal of this research study is to determine if the fecal microbiota transplant (FMT) improves the body's ability to fight your cancer.
- Trial name
- NCT03341143
- Testing
- Fecal Microbiota Transplant with Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Zarour, Hassane, MD
Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
This randomized phase II trial studies how well giving pembrolizumab with standard chemotherapy, tumor infiltrating lymphocytes (TIL), and aldesleukin works in treating patients with melanoma that has spread to other areas of the…
- Conditions
- Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Trial name
- NCT02500576
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Melanoma
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
This is a Phase II Evaluation of Docetaxel and Vinorelbine Plus Sargramostim in subjects who have metastatic melanoma which has advanced beyond the point at which local therapies such as surgery or radiation therapy would be…
- Trial name
- NCT00256282
- Testing
- Vinorelbine, Docetaxel, Sargramostim
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- John P. Fruehauf
Neuroendocrine Tumors, Carcinoid Tumors
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
The goal of this clinical research study is to learn if the study drug, Pasireotide LAR can shrink or slow the growth of Metastatic Neuroendocrine Carcinomas. The safety of this drug will also be studied.
- Trial name
- NCT01253161
- Testing
- Pasireotide Long Acting Release (LAR)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Metastatic Cancer
- Trial name
- NCT00730483
- Testing
- PVA microporous hydrospheres/doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Yale University
Neuroendocrine Tumors, Carcinoid Tumors
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors.
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
- Trial name
- NCT02441062
- Testing
- 68Ga-DOTATOC PET/CT
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Sue O'Dorisio
Melanoma (Skin)
Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma.
The purpose of this pilot study is to evaluate digitally supported skin self-examination compared to usual care in people treated for localised melanoma.
- Trial name
- MEL-SELF (NCT03581188)
- Testing
- Patient-led surveillance, Clinician-led surveillance
- Where
- 3 sites in Australia
- Volunteers
- 100 people
- Sponsor
- University of Sydney
Medullary Thyroid Cancer
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC.
- Trial name
- EXAMINER (NCT01896479)
- Testing
- Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg
- Where
- 49 sites in Australia, Canada and 12 more
- Volunteers
- 247 people
- Sponsor
- Exelixis
Advanced Solid Tumors, Metastatic Melanoma
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and multiple oral doses of encorafenib in combination with binimetinib on the single oral dose pharmacokinetics (PK) of cytochrome P450 (CYP)…
- Trial name
- NCT03864042
- Testing
- losartan, dextromethorphan, caffeine
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 56 people
- Sponsor
- Pfizer
Melanoma
Utility of Novel BRAF Test for Melanoma
This primary purpose of this study is to obtain blood samples from participants with both early and later stages of melanoma (Stage II/III and Stage IV).
- Trial name
- NCT01840527
- Where
- 3 sites in United States
- Volunteers
- 220 people
- Sponsor
- Massachusetts General Hospital
Melanoma
Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
Melanoma is an immune-modulated malignancy and immune checkpoint modulators which inhibit PD-1 function (pembrolizumab, nivolumab) have demonstrated clinical efficacy as treatment for patients with stage IV melanoma.
- Trial name
- NCT03241927
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Nina Bhardwaj
Melanoma
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
The primary objective was to estimate the proportion of participants with detectable talimogene laherparepvec deoxyribonucleic acid (DNA) in the blood and urine at any time after administration of talimogene laherparepvec within…
- Trial name
- NCT02014441
- Testing
- Talimogene laherparepvec
- Where
- 14 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Amgen
Malignant Melanoma, Neoplasms
A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
This open-label, multi-center, three-period, one sequence study will investigate the effect of vemurafenib on the pharmacokinetics of digoxin in patients with unresectable BRAFV600-mutation positive metastatic melanoma or other…
- Trial name
- NCT01765569
- Testing
- Digoxin, Vemurafenib
- Where
- 13 sites in Belarus, Israel and 3 more
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Advanced Digestive System Neuroendocrine Neoplasm, Duodenal Neuroendocrine Tumor G1
Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
This phase II trial studies how well ribociclib works in treating patients with neuroendocrine tumors of the foregut, which includes the thymus, lung, stomach, and pancreas, that have spread to other places in the body and…
- Conditions
- Advanced Digestive System Neuroendocrine Neoplasm, Duodenal Neuroendocrine Tumor G1, Functional Pancreatic Neuroendocrine Tumor, Gastric Neuroendocrine Tumor
- Trial name
- NCT02420691
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Ribociclib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center